bioMérieux S.A. (EPA:BIM)
France · Delayed Price · Currency is EUR | Market Cap | 13.02B |
| Revenue (ttm) | 4.12B |
| Net Income (ttm) | 377.90M |
| Shares Out | 118.07M |
| EPS (ttm) | 3.17 |
| PE Ratio | 34.80 |
| Forward PE | 22.62 |
| Dividend | 0.90 (0.82%) |
| Ex-Dividend Date | Jun 9, 2025 |
| Volume | 3,097 |
| Average Volume | 92,613 |
| Open | 110.30 |
| Previous Close | 110.30 |
| Day's Range | 109.80 - 110.40 |
| 52-Week Range | 101.70 - 128.30 |
| Beta | 0.65 |
| RSI | 59.72 |
| Earnings Date | Feb 27, 2026 |
About bioMérieux
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of... [Read more]
Financial Performance
In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.
Financial StatementsNews
bioMérieux S.A. (BMXXY) Analyst/Investor Day Transcript
bioMérieux S.A. (OTCPK:BMXXY) Analyst/Investor Day November 4, 2025 8:30 AM ESTCompany ParticipantsAymeric FichetPierre Boulud - Chief Executive...
BioMérieux S.A. (BMXXY) Q2 2025 Earnings Call Transcript
bioMérieux S.A. 2025 Q2 - Results - Earnings Call Presentation
The following slide deck was published by bioMérieux S.A.
bioMérieux S.A. (BMXMF) Q4 2024 Earnings Call Transcript
bioMérieux S.A. (BMXMF) Q2 2024 Earnings Call Transcript
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2021 Results - Earnings Call Transcript
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2021 Results - Earnings Call Transcript
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q3 2021 Results - Earnings Call Transcript
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q3 2021 Results - Earnings Call Transcript
bioMérieux: Pioneering In Vitro Diagnostics
bioMérieux is a leading developer and producer of in vitro diagnostic solutions with a focus on infectious diseases. The Company has a solid financial structure to support growth.
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2020 Results - Earnings Call Transcript
bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2020 Results - Earnings Call Transcript